Humira approved for juvenile rheumatoid arthritis

Article

Abbott's Humira (adalimumab) had been approved by the food and Drug Administration for its sixth indication, juvenile rheumatoid arthritis...

Abbott's Humira (adalimumab) has been approved by the Food and Drug Administration for its sixth indication, juvenile rheumatoid arthritis.

JVA joins other indications including chronic plaque psoriasis, rheumatoid arthritis in adults, and Crohn's disease.

Related Videos
FDA approves B-VEC to treat dystrophic epidermolysis bullosa patients 6 months and older | Image Credit: bankrx - Image Credit: bankrx - stock.adobe.com.
Related Content
© 2023 MJH Life Sciences

All rights reserved.